Graphene & Solar Technologies Limited (GSTX) 10-Q 13 Sep 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Jun. 30, 2023	Sep. 12, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--09-30
Entity File Number	333-174194
Entity Registrant Name	GRAPHENE & SOLAR TECHNOLOGIES LTD
Entity Central Index Key	0001497649
Entity Tax Identification Number	27-2888719
Entity Incorporation, State or Country Code	CO
Entity Address, Address Line One	23 Corporate Plaza Drive
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	Newport Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92660
City Area Code	(949)
Local Phone Number	478-8387
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		384,792,610

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Current Assets:
Cash	$ 6,495	$ 2,857
Prepaid expenses	11,404	11,183
Total Current Assets	17,899	14,040
Other Assets:
Furniture and equipment, net of depreciation $79,023	1,047	1,273
Intellectual property – at cost, net	1
Other intangible assets – at cost	975	975
Other receivable	4,015	2,094
Total Assets	23,937	18,382
Current Liabilities:
Accounts payable and other payable	2,550,540	2,380,565
Accrued interest payable	177,112	161,602
Due to related parties	1,838,093	1,342,405
Notes payable – in default	60,000	76,255
Convertible notes payable, net of discount $51,694 and $100,747 in default	100,747	100,747
Notes payable – Related Party	51,694
Total Current Liabilities	4,778,186	4,061,574
Total Liabilities	4,778,186	4,061,574
Preferred stock: 10,000,000 shares authorized; $0.00001 par value; no shares issued and outstanding
Common stock: 500,000,000 shares authorized; $0.00001 par value; 384,237,369 and 374,305,480 shares issued and outstanding	3,854	3,748
Additional paid-in capital	63,623,368	63,527,513
Stock Receivable	(795,000)	(795,000)
Accumulated deficit	(67,841,840)	(67,070,016)
Accumulated other comprehensive income	255,369	290,563
Total Stockholders’ Deficit	4,754,249	(4,043,192)
Total Liabilities and Stockholders’ Deficit	$ 23,937	$ 18,382

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Statement of Financial Position [Abstract]
Debt Discount	$ 51,694	$ 100,747
Perferred stock, authorized	10,000,000	10,000,000
Perferred stock, par value	$ 0.00001	$ 0.00001
Perferred stock, issued	0	0
Perferred stock, issued	0	0
Common stock, authorized	500,000,000	500,000,000
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, issued	384,237,369	374,305,480
Common stock, outstanding	384,237,369	374,305,480

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenues
Operating expenses
Professional Services	322,155	166,256	610,262	12,892,711
General and administrative	76,099	278,762	130,737	829,218
Total operating expenses	398,254	445,018	740,999	13,721,929
Loss from operations	(398,254)	(445,018)	(740,999)	(13,721,929)
Other income (expense)
Other income	8,116	7,288	25,078	18,564
Interest expense	(5,375)	(4,891)	(15,510)	(30,319)
Loss on extinguishment of debt	48		(40,393)
Total other income (expense)	2,789	2,397	(30,825)	(11,755)
Net Income (Loss)	(395,465)	(442,621)	(771,824)	(13,733,684)
Other Comprehensive Income	22,695	137,979	(35,194)	81,277
Net Comprehensive Loss	$ (372,770)	$ (304,644)	$ (807,018)	$ (13,652,409)
Income (Loss) per share:
Basic and diluted	$ 0	$ 0	$ 0	$ (0.04)
Weighted average shares outstanding	384,009,643	362,823,733	377,541,938	360,954,236

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIENCY - USD ($)	3 Months Ended						9 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2023	Jun. 30, 2022
Balance, March 31, 2022	$ (4,412,229)	$ (4,294,105)	$ (4,043,192)	$ 2,345,277	$ 2,833,038	$ 3,263,621	$ (4,043,192)	$ 3,263,621
Foreign currency translation adjustment	22,695	16,566	(74,455)	137,979	(47,456)	(9,246)
Net loss	(395,465)	(199,901)	(176,458)	(442,621)		(12,850,758)	(771,824)	(13,733,684)
Settlement of Notes		65,211
Stock-based compensation expense	30,750					12,382,500
Balance, June 30, 2022	(4,754,249)	(4,412,229)	(4,294,105)	2,040,635	2,345,277	2,833,038	(4,754,249)	2,040,635
Shares issued in connection with the sale of common stock						46,921
Common Stock [Member]
Balance, March 31, 2022	3,751	$ 3,748	$ 3,748	$ 3,633	$ 3,633	$ 3,437	$ 3,748	$ 3,437
Shares, Outstanding, Beginning Balance		374,542,610	374,305,480	362,823,733	362,823,733	343,237,369	374,305,480	343,237,369
Foreign currency translation adjustment
Net loss
Settlement of Notes		$ 3
Settlement of notes		237,130
Stock-based compensation expense	$ 103					$ 184
Stock-based compensation expense	10,250,000					18,386,364
Balance, June 30, 2022	$ 3,854	$ 3,751	$ 3,748	$ 3,633	$ 3,633	$ 3,633	$ 3,854	$ 3,633
Shares, Outstanding, Ending Balance	384,792,610		374,542,610	362,823,733	362,823,733	362,823,733	384,792,610	362,823,733
Shares issued in connection with the sale of common stock						$ 12
Shares issued in connection with the sale of common stock						1,200,000
Additional Paid-in Capital [Member]
Balance, March 31, 2022	$ 63,592,721	$ 63,527,513	$ 63,527,513	$ 62,427,147	$ 62,427,147	$ 49,922,922	$ 63,527,513	$ 49,922,922
Shares, Outstanding, Beginning Balance		374,305,480
Foreign currency translation adjustment
Net loss
Settlement of Notes		65,208
Stock-based compensation expense	30,647					12,382,316
Balance, June 30, 2022	63,623,368	63,592,721	$ 63,527,513	62,427,147	62,427,147	62,427,147	63,623,368	62,427,147
Shares, Outstanding, Ending Balance			374,305,480
Shares issued in connection with the sale of common stock						121,909
Stock Receivable [Member]
Balance, March 31, 2022	(795,000)	(795,000)	$ (795,000)	(795,000)	(795,000)	(720,000)	(795,000)	(720,000)
Foreign currency translation adjustment
Net loss
Settlement of Notes
Stock-based compensation expense
Balance, June 30, 2022	(795,000)	(795,000)	(795,000)	(795,000)	(795,000)	(795,000)	(795,000)	(795,000)
Shares issued in connection with the sale of common stock						(75,000)
Retained Earnings [Member]
Balance, March 31, 2022	(67,446,375)	(67,246,474)	(67,070,016)	(59,341,703)	(58,901,398)	(46,050,640)	(67,070,016)	(46,050,640)
Foreign currency translation adjustment
Net loss	(395,465)	(199,901)	(176,458)	(442,621)		(12,850,758)
Settlement of Notes
Stock-based compensation expense
Balance, June 30, 2022	(67,841,840)	(67,446,375)	(67,246,474)	(59,784,324)	(59,341,703)	(58,901,398)	(67,841,840)	(59,784,324)
Shares issued in connection with the sale of common stock
AOCI Attributable to Parent [Member]
Balance, March 31, 2022	232,674	216,108	290,563	51,200	98,656	107,902	290,563	107,902
Foreign currency translation adjustment	22,695	16,566	(74,455)	137,979	(47,456)	(9,246)
Net loss
Settlement of Notes
Stock-based compensation expense
Balance, June 30, 2022	$ 255,369	$ 232,674	$ 216,108	$ 189,179	$ 51,200	98,656	$ 255,369	$ 189,179
Shares issued in connection with the sale of common stock

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net Income (loss)	$ (771,824)	$ (13,733,684)
Adjustments to reconcile net income/(loss) to net cash from operating activities:
Stock-based compensation	30,750	12,382,500
Depreciation expense	254	611
Amortization of intangibles		735,096
Amortization of discount		13,943
Loss on Settlement of Debt	40,393
Change in operating assets and liabilities:
Accounts payable	167,158	225,056
Accrued interest payable	15,510	17,064
Accrued liabilities
Other Receivables	(1,921)	(2,094)
Pre-Payments
Due to related parties	472,730	312,045
Net cash used in operating activities	(46,950)	(49,463)
Cash flows from investing activities
Cash paid for purchase of fixed assets
Net cash used in investing activities
Cash flows from financing activities
Proceeds from issuance of common stock		46,921
Due to Affiliates	51,694
Issuance of short term note payable, net of OID
Net cash from financing activities	51,694	46,921
Effect of currency translations to cash flow	(1,106)	2,086
Net change in cash and cash equivalents	3,638	(456)
Beginning of period	2,857	3,728
End of period	6,495	3,272
Supplemental cash flow information
Interest paid
Taxes
Noncash investing and financing activities:
Settlement of Debt for Common Stock	$ 24,818

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
BASIS OF PRESENTATION	NOTE 1 – BASIS OF PRESENTATION These consolidated financial statements of Graphene & Solar Technologies Limited (GSTX or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results for the interim periods. Certain information, accounting policies and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to Securities and Exchange Commission (SEC) rules and regulations. These financial statements should be read along with Graphene & Solar Technologies audited financial statements as of September 30, 2022. Going Concern 67,841,838 Future issuances of the Company’s equity or debt securities will be required for the Company to finance operations and continue as a going concern. The financial statements do not include any adjustments that may result from the outcome of these uncertainties.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION	9 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Principles of Consolidation and Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). A summary of the significant accounting policies applied in the preparation of the accompanying financial statements can be found in the Company’s Annual Report in form 10-K for the year ended September 30, 2022. Use of Estimates Significant estimates include but are not limited to the estimated useful lives of equipment for purposes of depreciation and the valuation of common shares issued for services, equipment and the liquidation of liabilities. Cash and Cash Equivalents Derivative Financial Instruments The Company records all derivatives on the balance sheet at fair value, adjusted at the end of each reporting period to reflect any material changes in fair value, with any such changes classified as changes in derivatives valuation in the statement of operations. The calculation of the fair value of derivatives utilizes highly subjective and theoretical assumptions that can materially affect fair values from period to period. The recognition of these derivative amounts does not have any impact on cash flows. At the date of the conversion of any convertible debt, the pro rata fair value of the related embedded derivative liability is transferred to additional paid-in capital. There was no derivative activity in fiscal quarter ending June 30, 2023. Therefore, no derivative liabilities were recorded during the quarter ended June 30, 2023. Stock-Based Compensation “Compensation - Stock Compensation,” Foreign Currency Translations Earnings Per Share Reclassifications

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 3 – NOTES PAYABLE The Company’s indebtedness as of June 30, 2023 and September 30, 2022 were as follows: Schedule of notes payable Description June 30, 2023 September 30, 2022 Convertible notes $ 100,747 $ 100,747 Notes Payable $ 60,000 $ 76,255 Notes Payable – Related Parties $ 51,694 $ — Notes Payable and Other Loans During 2015 and 2016, the Company executed promissory notes payable with six individuals with an aggregate principal balance of $60,000. The notes were due on demand and included interest at 10%. As of June 30, 2023 and September 30, 2022, the total promissory notes payable balance was $107,197 and $102,710 including accrued interest of $47,197 and $42,710, respectively. On January 15, 2019, the holder of a note with a principal balance of $10,000 made demand for payment. To date, the note has not been paid. Convertible Notes Payable As of June 30, 2023 and September 30, 2022, noteholders representing $70,747 in outstanding principal had not requested the exchange of shares of common stock. As of June 30, 2023 and September 30, 2022, the exchange obligation payable was $176,835 and $168,897 including accrued interest of $106,087 and $98,150, respectively. As of June 30, 2023 and September 30, 2022, the exchange obligation was for 53,424 shares and 51,026 shares of common stock, respectively. On February 1, 2016, the Company issued convertible secured note payable of $30,000 to an individual. The note was due on January 31, 2017 and included interest at 10%. The note was convertible at discretion of the holder into common shares of the Company at the rate of $0.50 per shares. The Company has not extended the maturity date and the note is in default. As of June 30, 2023 and September 30, 2022, the total convertible note payable balance was $52,241 and $49,997, including accrued interest of $22,241 and $19,997 respectively. As of June 30, 2023 and September 30, 2022, the exchange obligation was for 104,482 shares and 99,994 shares of common stock, respectively. Related Party Loans On December 5, 2022, the Company entered into a Promissory Loan Note with Mr. Andrew Liang, in the amount of US$20,000, with a maturity date of December 5, 2023. The loan will accrue interest at the rate of 10% per annum. On February 28, 2023, the Company entered into a Promissory Loan Note with MI Labs Pty Ltd, in the amount of US$50,000 (of which $31,693 was received by the company as of June 30, 2023) with a maturity date of February 28, 2024. The loan will accrue interest at the rate 10% per annum.

RELATED PARTY

RELATED PARTY	9 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY	NOTE 4- RELATED PARTY MI Labs Pty Ltd, a management company controlled by Mr. Jason May, the Company’s Chief Executive Officer and a Company Director, provides management services to the Company for which the Company is charged $25,000 monthly. During the nine months ended June 30, 2023, the Company incurred charges to operations of $125,000 with respect to this arrangement. CSA Liang Pty Ltd, a management company controlled by Mr. Andrew Liang, a Company Director and former Chief Executive Officer, provided management services to the Company for which the Company was charged $20,833 monthly. During the nine months ended June 30, 2023, the Company incurred charges to operations of $187,497 with respect to this arrangement. Sativus Investments, a management company controlled by Mr. Paul Saffron, the Company’s Chief Operations Officer, provides management services to the Company for which the Company is charged $20,000 monthly, plus a $60,000 sign-on bonus. During the nine months ended June 30, 2023, the Company incurred charges to operations of $100,000 with respect to this arrangement. During nine-months period ended June 30, 2023 and 2022, stock-based compensation expense relating to directors, officers, affiliates and related parties was $0 (0 shares) and $2,485,000

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	9 Months Ended
	Jun. 30, 2023
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 5 – STOCKHOLDERS’ EQUITY During the quarter ended June 30, 2023, the Company issued 10,250,000 shares of the Company’s common stock to members of the Board of Directors, employees, and consultants. The fair value of the shares, as determined by reference market price of the Company’s common stock on each grant date, aggregated $30,750. Total stock-based compensation expense was $30,750 for the nine-months ended June 30, 2023. 237,130 new common shares were issued during the nine- month period ending June 30, 2023 for settlement of debt and liabilities totaling $65,211. The company recognized a loss of $40,393 on this exchange. The Company has a total of 5,778,366 shares that remain approved, reserved and outstanding and not yet issued by the Transfer Agent at June 30, 2023.

COMMITMENTS & CONTINGENCIES

COMMITMENTS & CONTINGENCIES	9 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS & CONTINGENCIES	NOTE 6 – COMMITMENTS & CONTINGENCIES Contingencies From time to time, we may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate) may materially and adversely affect our financial condition, results of operations and liquidity. In addition, the ultimate outcome of any litigation is uncertain. Any outcome, whether favorable or unfavorable, may materially and adversely affect us due to legal costs and expenses, diversion of management attention and other factors. We expense legal costs in the period incurred. We cannot assure you that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against us in the future, and these matters could relate to prior, current or future transactions or events. As of June 30, 2023, there were no pending or threatened litigation against the Company.

INTANGIBLE ASSETS_PATENTS

INTANGIBLE ASSETS/PATENTS	9 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS/PATENTS	NOTE 7 – INTANGIBLE ASSETS/PATENTS We amortize capitalized patent costs for internally generated patents on a straight-line basis for 7 years, which represents the estimated useful lives of the patents. The seven-year estimated useful life for internally generated patents is based on our assessment of such factors as: the integrated nature of the portfolios being licensed, the overall makeup of the portfolio over time, and the length of license agreements for such patents. The estimated useful lives of acquired patents and patent rights, however, have been and will continue to be based on a separate analysis related to each acquisition and may differ from the estimated useful lives of internally generated patents. The average estimated useful life of acquired patents is 6.7 years. We assess the potential impairment to all capitalized net patent costs when events or changes in circumstances indicate that the carrying amount of our patent portfolio may not be recoverable. Schedule of finite lived intangible assets June 30, 2023 June 30, 2022 Patents 1 6,879,745 Accumulated amortization — (837,417 ) Total patent costs, net 1 6,042,328

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS On April 2, 2023, Mr. Jason May was appointed Chief Executive Officer by the Board of Directors. Mr. May was granted 2,000,000 shares per the terms of the agreement. As of this filing date, the 2,000,000 shares have been approved but remain unissued. On June 1, 2023, Mr. Paul Saffron was appointed Chief Operations Officer by the Board of Directors. Mr. Saffron was granted 5,000,000 shares per the terms of the agreement. As of this filing date, the 5,000,000 shares have been approved but remain unissued. On July 1, 2023, Mr. Andrew Liang stepped down from the Chief Executive Officer role but remains a Corporate Advisor and a Director on the Board. Mr. Liang was granted 10,000,000 shares per the terms of the agreement. As of this filing date, the 10,000,000 shares have been approved but remained unissued. On July 28, 2023, Mr. Juan Hilsaca signed a consulting agreement with the Company and was granted 250,000 shares per the terms of the agreement. As of this filing date, the 250,000 shares have been approved but remained unissued. Mr. Thomas Chang was granted a maximum of 1,000,000 shares per annum subject to performance in fiscal years 2021/2022, 2022/2023 and 2023/2024 to a total of 3,000,000 shares. 1,000,000 shares were issued during the 2021/2022 fiscal year. As of this filing date, the remaining 2,000,000 shares have been approved but remain unissued. The Company has evaluated events occurring subsequent to June 30, 2023 through to the date these financial statements were issued and has identified no additional events requiring disclosure.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies)	9 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). A summary of the significant accounting policies applied in the preparation of the accompanying financial statements can be found in the Company’s Annual Report in form 10-K for the year ended September 30, 2022.
Use of Estimates	Use of Estimates Significant estimates include but are not limited to the estimated useful lives of equipment for purposes of depreciation and the valuation of common shares issued for services, equipment and the liquidation of liabilities.
Cash and Cash Equivalents	Cash and Cash Equivalents
Derivative Financial Instruments	Derivative Financial Instruments The Company records all derivatives on the balance sheet at fair value, adjusted at the end of each reporting period to reflect any material changes in fair value, with any such changes classified as changes in derivatives valuation in the statement of operations. The calculation of the fair value of derivatives utilizes highly subjective and theoretical assumptions that can materially affect fair values from period to period. The recognition of these derivative amounts does not have any impact on cash flows. At the date of the conversion of any convertible debt, the pro rata fair value of the related embedded derivative liability is transferred to additional paid-in capital. There was no derivative activity in fiscal quarter ending June 30, 2023. Therefore, no derivative liabilities were recorded during the quarter ended June 30, 2023.
Stock-Based Compensation	Stock-Based Compensation “Compensation - Stock Compensation,”
Foreign Currency Translations	Foreign Currency Translations
Earnings Per Share	Earnings Per Share
Reclassifications	Reclassifications

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	9 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of notes payable	Schedule of notes payable Description June 30, 2023 September 30, 2022 Convertible notes $ 100,747 $ 100,747 Notes Payable $ 60,000 $ 76,255 Notes Payable – Related Parties $ 51,694 $ —

INTANGIBLE ASSETS_PATENTS (Tabl

INTANGIBLE ASSETS/PATENTS (Tables)	9 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of finite lived intangible assets	Schedule of finite lived intangible assets June 30, 2023 June 30, 2022 Patents 1 6,879,745 Accumulated amortization — (837,417 ) Total patent costs, net 1 6,042,328

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative)	156 Months Ended
	Jun. 30, 2023 USD ($)
Accounting Policies [Abstract]
Net losses	$ 67,841,838

Schedule of notes payable (Deta

Schedule of notes payable (Details) - USD ($)	Jun. 30, 2023	Sep. 30, 2022
Debt Disclosure [Abstract]
Convertible notes	$ 100,747	$ 100,747
Notes Payable	60,000	76,255
Notes Payable – Related Parties	$ 51,694

Schedule of finite lived intang

Schedule of finite lived intangible assets (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 1	$ 6,879,745
Accumulated amortization		(837,417)
Total patent costs, net	$ 1	$ 6,042,328